T1	Participants 58 118	patients with refractory advanced non-small-cell lung cancer
T2	Participants 374 445	patients with locally advanced or metastatic non-small-cell lung cancer
T3	Participants 455 542	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
T4	Participants 736 761	those with adenocarcinoma
T5	Participants 1236 1268	812 patients with adenocarcinoma
T6	Participants 1440 1460	never-smokers (n=375
T7	Participants 1528 1559	patients of Asian origin (n=342
